Original release date: January 21, 2021
Access to this course expires on: July 21, 2021 at 11:59 PM Pacific Time
Lung adenocarcinoma represents a histologically diverse tumor with challenges in classification and grading that have staging and prognostic impact. With the concept of pre-invasive neoplasia has come new approaches to measurement of invasive size, and these methods have been incorporated into AJCC staging. Invasive size assessments vary by observer and therefore standardization through review and education are vital to increase reliability and properly prognosticate. A new system of grading lung adenocarcinoma has been proposed, and this new system incorporates pattern-based classification.
Practicing academic and community pathologists, and pathologists-in-training
Upon completion of this educational activity, learners will be able to
Continuing Medical Education
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported no relevant financial relationships: Alain C. Borczuk, MD
USCAP staff associated with the development of content for this activity reported no relevant financial relationships.